Futura Medical recommended for CSD500 approval
Futura Medical - the pharmaceutical group that develops innovative products for consumer healthcare - has been informed that the relevant notified body is satisfied that all outstanding points in the regulatory dossier for CSD500 have been resolved and has been recommended to their Review Panel for approval.
The panel's approval process typically takes a month and is already under way.
The CE mark certificate will enable CSD500 to be marketed and sold within 29 European territories and a number of other non-European territories that recognise the CE mark process.
Reckitt Benckiser, makers of the Durex branded condom, have exclusive global rights to CSD500.
At 8:02am: (LON:FUM) Futura Medical share price was +7.5p at 91.5p
Story provided by StockMarketWire.com
